Summary:
- This study investigates the association between the use of glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide and liraglutide—and the risk of developing suicidal ideation.
- Utilizing a large-scale analysis of electronic health records, the researchers found no significant increase in the risk of suicidal ideation among patients prescribed GLP-1 receptor agonists compared with those prescribed other antiobesity or antidiabetic medications.